巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    OpGen

    OPGN
    0.580
    0.010
    1.31%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・OpGen - 延遲價格・最後更新於 10/08 9:30
    最高位
    0.589
    最低位
    0.566
    開市價
    --
    前收市價
    0.588
    成交量(千)
    1.44
    成交額(百萬)
    0.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    27.03
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.720 - 0.310
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    OpGen
    證券代碼
    OPGN.US
    所屬板塊
    Diagnostics & Research
    公司業務
    OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
    發行量
    46558250
    公司總部
    9717 Key West Avenue, Suite 100
    公司網址
    http://www.opgen.com
    公司電郵
    CustomerSupport@OpGen.com
    公司電話
    +1 240 813-1260
    暫無內容

    關於

    OpGen(OPGN.US)所屬的行業板塊為Diagnostics & Research。
    OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
    詳細公司背景可參考: http://www.opgen.com